Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 12/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.35 |
| ▸ | LCK | P06239 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.30 |
| ▸ | MARK3 | P27448 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784636 | 0.91 | PTK6 (0.37) | PTK6AURKBLCKPIK3CAROCK2 | |
| SCHEMBL3688399 | 0.91 | LCK (0.33) | PTK6AURKBLCKPIK3CAROCK2 | |
| SCHEMBL3784631 | 0.89 | PTK6 (0.34) | PTK6AURKBLCKPIK3CAMARK3 | |
| SCHEMBL3704092 | 0.88 | PTK6 (0.35) | PTK6AURKBLCKROCK2MARK3 | |
| SCHEMBL3709902 | 0.87 | KDM4E (0.35) | PTK6AURKBLCKPIK3CAROCK2 | |
| SCHEMBL3787040 | 0.86 | AURKB (0.35) | PTK6AURKBLCKPIK3CAROCK2 | |
| SCHEMBL3691038 | 0.86 | PTK6 (0.35) | PTK6AURKBLCKROCK2MARK3 | |
| SCHEMBL3788870 | 0.86 | PTK6 (0.35) | PTK6AURKBLCKPIK3CAROCK2 | |
| SCHEMBL3793199 | 0.86 | PTK6 (0.35) | PTK6AURKBLCKPIK3CAROCK2 | |
| SCHEMBL13228896 | 0.85 | PTK6 (0.34) | PTK6AURKBLCKPIK3CAROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | claimed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | PTK6 4396/4885AURKB 1908/4885LCK 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.